Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23066

1.

LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer.

Nagata H, Ishihara S, Abe H, Ushiku T, Kishikawa J, Tanaka T, Hata K, Kawai K, Fukayama M, Nozawa H.

Br J Cancer. 2019 Apr 19. doi: 10.1038/s41416-019-0442-5. [Epub ahead of print]

PMID:
31000786
2.

A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide.

Chen X, Wang F, Zhang Y, Teng W, Cao P, Ma X, Liu M, Tian Y, Wang T, Nie D, Zhang J, Liu H, Wang W.

Br J Cancer. 2019 Apr 18. doi: 10.1038/s41416-019-0456-z. [Epub ahead of print]

PMID:
30996344
3.

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

Mak G, Soria JC, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, Rizzuto I, Greystoke A, Yan L, Tolson J, Auger KR, Arkenau HT.

Br J Cancer. 2019 Apr 17. doi: 10.1038/s41416-019-0452-3. [Epub ahead of print]

PMID:
30992546
4.

Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.

Horn J, Denecke A, Luyten A, Rothe B, Reinecke-Lüthge A, Mikolajczyk R, Petry KU.

Br J Cancer. 2019 Apr 16. doi: 10.1038/s41416-019-0453-2. [Epub ahead of print]

PMID:
30988395
5.

Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts.

Xu X, Zhu L, Yang Y, Pan Y, Feng Z, Li Y, Chang W, Sui J, Cao F.

Br J Cancer. 2019 Apr 16. doi: 10.1038/s41416-019-0450-5. [Epub ahead of print]

PMID:
30988394
6.

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).

Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S; Swiss Group of Clinical Cancer Research (SAKK).

Br J Cancer. 2019 Apr 16. doi: 10.1038/s41416-019-0447-0. [Epub ahead of print]

PMID:
30988393
7.

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer.

Daulat AM, Finetti P, Revinski D, Silveira Wagner M, Camoin L, Audebert S, Birnbaum D, Kodjabachian L, Borg JP, Bertucci F.

Br J Cancer. 2019 Apr 11. doi: 10.1038/s41416-019-0448-z. [Epub ahead of print]

PMID:
30971775
8.

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.

Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.

Br J Cancer. 2019 Apr 11. doi: 10.1038/s41416-019-0446-1. [Epub ahead of print]

PMID:
30971774
9.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J; SOLE Investigators.

Br J Cancer. 2019 Apr 10. doi: 10.1038/s41416-019-0435-4. [Epub ahead of print]

PMID:
30967649
10.

Family history of cancer and risk of paediatric and young adult's testicular cancer: A Norwegian cohort study.

Del Risco Kollerud R, Ruud E, Haugnes HS, Cannon-Albright LA, Thoresen M, Nafstad P, Vlatkovic L, Blaasaas KG, Næss Ø, Claussen B.

Br J Cancer. 2019 Apr 10. doi: 10.1038/s41416-019-0445-2. [Epub ahead of print]

PMID:
30967648
11.

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.

Rasmussen JH, Lelkaitis G, Håkansson K, Vogelius IR, Johannesen HH, Fischer BM, Bentzen SM, Specht L, Kristensen CA, von Buchwald C, Wessel I, Friborg J.

Br J Cancer. 2019 Apr 10. doi: 10.1038/s41416-019-0449-y. [Epub ahead of print]

PMID:
30967647
12.

Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.

Heim L, Kachler K, Siegmund R, Trufa DI, Mittler S, Geppert CI, Friedrich J, Rieker RJ, Sirbu H, Finotto S.

Br J Cancer. 2019 Apr 8. doi: 10.1038/s41416-019-0444-3. [Epub ahead of print]

PMID:
30956278
13.

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.

Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V.

Br J Cancer. 2019 Apr 4. doi: 10.1038/s41416-019-0443-4. [Epub ahead of print]

PMID:
30944458
14.

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.

Moon JH, Hong SW, Kim JE, Shin JS, Kim JS, Jung SA, Ha SH, Lee S, Kim J, Lee DH, Park YS, Kim DM, Park SS, Hong JK, Kim DY, Kim EH, Jung J, Kim MJ, Kim SM, Deming DA, Kim K, Kim TW, Jin DH.

Br J Cancer. 2019 Apr 4. doi: 10.1038/s41416-019-0434-5. [Epub ahead of print]

PMID:
30944457
15.

Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer.

Kather JN, Halama N.

Br J Cancer. 2019 Apr 2. doi: 10.1038/s41416-019-0441-6. [Epub ahead of print] Review.

PMID:
30936499
16.

The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study.

O'Connell RL, Rattay T, Dave RV, Trickey A, Skillman J, Barnes NLP, Gardiner M, Harnett A, Potter S, Holcombe C; iBRA-2 Steering Group; Breast Reconstruction Research Collaborative.

Br J Cancer. 2019 Mar 29. doi: 10.1038/s41416-019-0438-1. [Epub ahead of print]

PMID:
30923359
17.

How rapid advances in imaging are defining the future of precision radiation oncology.

Beaton L, Bandula S, Gaze MN, Sharma RA.

Br J Cancer. 2019 Apr;120(8):779-790. doi: 10.1038/s41416-019-0412-y. Epub 2019 Mar 26. Review.

PMID:
30911090
18.

Can proton therapy be considered a standard of care in oncology? Lessons from the United States.

Zietman AL.

Br J Cancer. 2019 Apr;120(8):775-776. doi: 10.1038/s41416-018-0324-2. Epub 2019 Mar 26. No abstract available.

PMID:
30911089
19.

Comment on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis".

Péré H, Pavie J, Pernot S, Veyer D, Bertaud D, Hurel S, Bélec L, Hans S, Ménard M, Cochand-Priollet B, Weiss L, Bats AS, Badoual C; AP-HP CoMPap (Consultation Multidisciplinaire Papillomavirus) group.

Br J Cancer. 2019 Mar 26. doi: 10.1038/s41416-019-0439-0. [Epub ahead of print] No abstract available.

PMID:
30911088
20.

Comment on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis".

Jayaraj R, Kumarasamy C.

Br J Cancer. 2019 Mar 26. doi: 10.1038/s41416-019-0437-2. [Epub ahead of print] No abstract available.

PMID:
30911087

Supplemental Content

Loading ...
Support Center